Shares of Eidos Therapeutics Inc (NASDAQ:EIDX) have earned an average recommendation of “Buy” from the eight brokerages that are covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, two have given a hold recommendation and five have issued a buy recommendation on the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $30.20.
EIDX has been the topic of several research analyst reports. BTIG Research set a $14.00 price target on ARBOR RLTY TR I/SH and gave the company a “buy” rating in a research note on Wednesday, April 17th. BMO Capital Markets downgraded Capital Power from an “outperform” rating to a “market perform” rating in a research note on Wednesday, May 8th. Finally, Zacks Investment Research downgraded ExlService from a “hold” rating to a “sell” rating in a research note on Wednesday, July 10th.
EIDX stock traded down $1.61 on Wednesday, hitting $39.14. 236,303 shares of the company’s stock were exchanged, compared to its average volume of 144,430. Eidos Therapeutics has a 12-month low of $8.89 and a 12-month high of $41.35. The stock’s 50 day simple moving average is $32.70. The company has a current ratio of 19.04, a quick ratio of 19.04 and a debt-to-equity ratio of 0.01. The firm has a market capitalization of $1.50 billion and a PE ratio of -21.04.
Eidos Therapeutics (NASDAQ:EIDX) last announced its earnings results on Tuesday, May 7th. The company reported ($0.32) earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.32). As a group, sell-side analysts forecast that Eidos Therapeutics will post -1.73 earnings per share for the current year.
In other news, insider Uma Sinha sold 5,000 shares of the company’s stock in a transaction dated Thursday, May 23rd. The stock was sold at an average price of $27.28, for a total value of $136,400.00. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CFO Christine Siu sold 17,000 shares of the company’s stock in a transaction dated Wednesday, June 5th. The stock was sold at an average price of $29.97, for a total value of $509,490.00. The disclosure for this sale can be found here. In the last quarter, insiders have sold 72,000 shares of company stock worth $2,305,940.
Institutional investors and hedge funds have recently modified their holdings of the company. Metropolitan Life Insurance Co NY purchased a new stake in Eidos Therapeutics in the 1st quarter valued at approximately $143,000. MetLife Investment Advisors LLC purchased a new stake in shares of Eidos Therapeutics during the 1st quarter worth approximately $198,000. Fiduciary Trust Co. purchased a new stake in shares of Eidos Therapeutics during the 1st quarter worth approximately $211,000. American International Group Inc. boosted its stake in shares of Eidos Therapeutics by 2.3% during the 1st quarter. American International Group Inc. now owns 245,362 shares of the company’s stock worth $5,754,000 after acquiring an additional 5,586 shares in the last quarter. Finally, Candriam Luxembourg S.C.A. boosted its stake in shares of Eidos Therapeutics by 193.1% during the 1st quarter. Candriam Luxembourg S.C.A. now owns 425,000 shares of the company’s stock worth $9,967,000 after acquiring an additional 280,000 shares in the last quarter. Hedge funds and other institutional investors own 34.01% of the company’s stock.
About Eidos Therapeutics
Eidos Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on developing drugs to treat diseases caused by transthyretin (TTR) amyloidosis (ATTR). It is developing AG10, an orally-administered small molecule designed to stabilize tetrameric TTR, thereby halting at its outset the series of molecular events that give rise to ATTR.
Featured Article: What is the Gross Domestic Product (GDP)?
Receive News & Ratings for Eidos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eidos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.